Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...
Eli Lilly and Co. to open a research lab that will use artificial intelligence to speed up drug discovery. The companies ...
As 2025 progressed, AI enthusiasm evolved into cross-industry concerns over the increasing likelihood of an "AI bubble." In ...
Lilly Nvidia launch drug AI lab in the Bay Area with $1B investment to speed drug discovery using advanced AI and robotics.
Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...
NVIDIA (NVDA) on Monday said it is expanding its BioNeMo platform for AI-driven biology and drug discovery, unveiling new software models, data tools and partnerships aimed at linking artificial ...
Nvidia (NASDAQ:NVDA) expanded its BioNeMo platform with new models, tools and data-processing libraries aimed at connecting ...
Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...
From left, Julien Loiseau, Al McPherson and Christoph Junghans. Photo Courtesy LANL Top: Julien Loiseau, center, with Al ...
From lab space and coffee bars to jobs and long-term returns, mid-tier life sciences hubs may be better positioned than the biggest biotech boomtowns.
The move targets harnesses—software wrappers that pilot a user’s web-based Claude account via OAuth to drive automated ...
MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback